Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
May 29, 2024 08:00 ET
|
Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
Vyluma Announces Marketing Authorization Application Validation for the European Union
May 29, 2024 07:30 ET
|
Vyluma, Inc.
Vyluma announces Marketing Authorisation Application (MAA) validation for the EU for NVK002 to slow the progression of pediatric myopia.
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024 16:30 ET
|
Cellectis Inc.
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference...
Rentschler Biopharma Appoints Patrick Meyer as Global Head BD Sales and Alliance Management
May 28, 2024 07:00 ET
|
Rentschler Biopharma SE
LAUPHEIM, Germany and MILFORD, Mass. and STEVENAGE, United Kingdom, May 28, 2024 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization...
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
May 28, 2024 07:00 ET
|
NodThera
NodThera INC (“NodThera” or the “Company”) NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership...
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
May 27, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Rhino Health and Medinexo Partner to Expand Data Diversity in Therapeutic Development
May 22, 2024 15:35 ET
|
Rhino Health
Rhino Health and Medinexo are partnering to provide federated access to a global network of hospitals to accelerate biopharma research.
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
May 22, 2024 07:00 ET
|
Entero Therapeutics, Inc.
BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage...
Blue Mountain Appoints Chief Growth Officer to Spearhead Global Expansion and Strategic Partnerships in Life Sciences Sector
May 21, 2024 09:00 ET
|
Blue Mountain
Blue Mountain names Keith Pensabene as Chief Growth Officer, leading global growth and strategic partnerships in the life sciences sector.
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference
May 20, 2024 07:00 ET
|
Entero Therapeutics, Inc.
BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...